Adjuvant therapy in stage i carcinoma of the breast: The influence of multigene analyses and molecular phenotyping

Cancer

Volumn 118, Issue 8, 2012, Pages 2031-2038

  Schwartz, Gordon F ^a   Reis Fihlo, Jorge ^b   Pusztai, Lajos ^c   Fentiman, Ian S ^d   Holland, Roland ^e   Bartelink, Harry ^f   Rutgers, Emiel J T ^g   Solin, Lawrence J ^h   Palazzo, Juan ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GUY S HOSPITAL   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^h ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

adjuvant; breast cancer; chemotherapy; gene expression; hormone receptors

Indexed keywords

AROMATASE INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER GRADING; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SIZE; CANCER STAGING; CONSENSUS DEVELOPMENT; DEMOGRAPHY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HUMAN; LOCAL EXCISION; MASTECTOMY; MEDICAL DECISION MAKING; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENTINEL LYMPH NODE BIOPSY; SUBMICROMETASTASIS; TREATMENT INDICATION;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PRACTICE GUIDELINES AS TOPIC;

EID: 84859630631     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27431     Document Type: Article

References (32)

1. National Cancer Institute. Clinical Alert. Bethesda, MD. National Cancer Institute; 1988.
2. Boyages J, Taylor R, Ung O, et al. A risk index for early node-negative breast cancer. Br J Surg. 2006; 93: 564-571.
3. Dignam JJ, Dukic V, Andersen SJ, et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009; 116: 595-602.
4. Dowsett M, Salter J, Zabaglo L, et al. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011; 76: 770-780.
5. Campbell HE, Taylor MA, Harris AL, Gray AM,. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer. 2009; 101: 1074-1084.
6. Schwartz GF, Giuliano A, Veronesi U,; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 2542-2551.
7. Jayasinghe UW, Taylor R, Boyages J,. Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg. 2005; 75: 762-767.
8. Page DL, Jensen RA, Simpson JF,. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998; 51: 195-208.
9. Muss HB, Berry DZ, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009; 360: 2055-2065.
10. Viale G, Regan MM, Maiorano E, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptorsa-International Breast Cancer Study Group. J Clin Oncol. 2008; 26: 1404-1410.
11. Isakoff SJ,. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010; 16: 53-61.
12. Kashiwagi S, Yashiro M, Takashima T, et al. Significance of E-cadherin expression in triple negative breast cancer. Br J Cancer. 2010; 103: 249-255.
13. Solin LJ, Hwang W-T, Vapiwala H,. Outcome after breast conservation treatment with radiation for women with triple-negative early stage breast cancer. Clin Breast Cancer. 2009; 9: 96-100.
14. Colleoni M, Cole BF, Viale G, et al. Classical cyclophosphamide, methotrexate, and fluorouracil is more effective in triple-negative, node-negative breast caner: results from 2 randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010; 28: 2966-2973.
15. Tischkowitz M, Brunet J-S, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer [serial online]. BMC Cancer. 2007; 7: 134.
16. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast cancers. Nature. 2000; 406: 747-752.
17. Seal MD, Chia SK,. What is the difference between triple-negative and basal breast cancers? Cancer J. 2010; 16: 12-16.
18. Sotiriou C, Pusztai L,. Gene expression signatures in breast cancer. N Engl J Med. 2009; 360: 790-800.
19. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a 5-biomarker panel. J Clin Oncol. 2009; 27: 4701-4708.
20. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.
21. Nuyten DSA, Kreike B, Hart AAM, et al. Predicting a local recurrence after breast conserving therapy by gene expression profiling [serial online]. Breast Cancer Res. 2006; 8: R62.
22. Dowsett M, Cusick J, Wale C, et al. Prediction of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28: 1829-1834.
23. Sparano JA, Paik S,. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008; 26: 721-728.
24. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008; 26: 729-735.
25. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010; 28: 1677-1683.
26. Millar EK, Graham PH, McNeil CM, et al. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel. Br J Cancer. 2011; 105: 272-280.
27. Mook S, Knauer M, Bueno-de-Mesquita JM, et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg. Oncol. 2010; 17: 1406-1413.
28. Harris L, Fritsche H, Mennel R, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25: 5287-5312.
29. Cianfrocca M, Gradishar W,. New molecular classifications of breast cancer. CA Cancer J Clin. 2009; 59: 303-313.
30. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27: 1160-1167.
31. Voduc KD, Cheug MCU, Tyldesley S, Gelman K, Nielsen TO, Kennecke H,. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28: 1684-1691.
32. Sims AH, Ong KR, Clarke RB, Howell A,. High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic? Breast Cancer Res. 2006; 8: 214-220.